SEC For	m 4																		
FORM 4 UNI				UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549												OMB APPROVAL			
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).					pursua	nt to Sec	tion 16(a)	of the Se	ecuriti	SEFICIA es Exchang npany Act o	_	HIP	Estim	Number ated ave per resp	erage burder	3235-0287 1 0.5			
1. Name and Address of Reporting Person [*] <u>Kaye Edward M. MD</u>					2. Issuer Name and Ticker or Trading Symbol <u>Stoke Therapeutics, Inc.</u> [STOK]								5. Relationship of Reporting Person (Check all applicable) X Director			n(s) to Issu 10% Ov			
(Last) (First) (Middle) C/O STOKE THERAPEUTICS, INC.					3. Date of Earliest Transaction (Month/Day/Year) 12/01/2023								X Officer (give title Other (specify below) CEO				specify		
45 WIGGINS AVENUE (Street)				[4. If Amendment, Date of Original Filed (Month/Day/Year)							Line	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person						
BEDFORD MA 01730					F									Form filed by More than One Reporting Person					
(City) (State) (Zip)					Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.														
		Т	able I - Nor	n-Deriva	tive S	ecurit	ies Acq	uired,	Dis	posed of	, or Ben	eficially	Owned						
Date			2. Transac Date (Month/Da		if any	emed ion Date, /Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4			and 5) Securities Beneficially Owned Follo		Form:	Direct Indirect tr. 4)	7. Nature of Indirect Beneficial Ownership			
								Code	v	Amount	(A) or (D)	Price	Reported Transactio (Instr. 3 an				(Instr. 4)		
			Table II - I							osed of, o onvertib			Jwned						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Yea	Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercise Expiration Date (Month/Day/Yea		e of Securities		ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported		10. Ownershij Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisa	able	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)					
Employee Stock Option (Right to	\$60	12/01/2023		D			200,800	(1)		03/01/2031	Common Stock	200,800) (2)	0		D			

Explanation of Responses:

(3)

1. The canceled option vested as to 1/48th of the total award on April 2, 2021 and provided for 1/48th of the total award to vest monthly thereafter, subject to the reporting person's continued service to the Issuer through each vesting date.

(4)

2. On December 1, 2023, the Issuer cancelled, pursuant to the Issuer's option exchange program, options to purchase 200,800 shares of Common Stock of the Issuer and in exchange issued to the reporting person 25,908 restricted stock units.

3. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.

4. 21,591 restricted stock units will vest on December 1, 2024 and 4,317 will vest on December 1, 2025, subject to the reporting person's continued service to the Issuer on each such date.

25,908

Remarks:

Buy) Restricted

Stock Unit (RSU)

> /s/ Stephen Tulipano, Attorneyin-Fact 12/05/2023

** Signature of Reporting Person Date

25,908

\$0.00

25,908

D

Common Stock

12/01/2025

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

12/01/2023

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Α

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.